Increased expressions of SATB1 and S100A4 are associated with poor prognosis in human colorectal carcinoma

APMIS

Volumn 123, Issue 2, 2015, Pages 93-101

  Niu, Yanfeng ^a   Wang, Lixia ^a   Cheng, Chao ^a   Du, Chao ^a   Lu, Xiaoming ^a   Wang, Guobin ^a   Liu, Jun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Colorectal carcinoma; Prognosis; S100A4; SATB1; Survival

Indexed keywords

CALVASCULIN; SPECIAL AT RICH SEQUENCE BINDING PROTEIN 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; MATRIX ATTACHMENT REGION BINDING PROTEIN; PROTEIN S 100; S100A4 PROTEIN, HUMAN; SATB1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; AT RICH SEQUENCE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CARCINOMA; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; BIOSYNTHESIS; COLORECTAL TUMOR; DISEASE COURSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MATRIX ATTACHMENT REGION BINDING PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; S100 PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84921451417     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12310     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Wang H, Huang H, Li W, Jin X, Zeng J, Y Liu, et al. Nuclear localization of 14-3-3epsilon inversely correlates with poor long-term survival of patients with colorectal cancer. J Surg Oncol 2012;106:224-31.
3. Zeng J, Yang X, Cheng L, Liu R, Lei Y, Dong D, et al. Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection. J Transl Med 2013;11:6.
4. Huerta S. Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Rev Mol Diagn 2008;8:277-88.
5. Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, Kohwi-Shigematsu T. The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev 2000;14:521-35.
6. Notani D, Gottimukkala KP, Jayani RS, Limaye AS, Damle MV, Mehta S, et al. Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner. PLoS Biol 2010;8:e1000296.
7. Cai S, Han HJ, Kohwi-Shigematsu T. Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat Genet 2003;34:42-51.
8. Kumar PP, Bischof O, Purbey PK, Notani D, Urlaub H, Dejean A, et al. Functional interaction between PML and SATB1 regulates chromatin-loop architecture and transcription of the MHC class I locus. Nat Cell Biol 2007;9:45-56.
9. Pavan Kumar P, Purbey PK, Sinha CK, Notani D, Limaye A, Jayani RS, et al. Phosphorylation of SATB1, a global gene regulator, acts as a molecular switch regulating its transcriptional activity in vivo. Mol Cell 2006;22:231-43.
10. Agrelo R, Souabni A, Novatchkova M, Haslinger C, Leeb M, Komnenovic V, et al. SATB1 defines the developmental context for gene silencing by Xist in lymphoma and embryonic cells. Dev Cell 2009;16:507-16.
11. Chen H, Takahara M, Oba J, Xie L, Chiba T, Takeuchi S, et al. Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma. J Dermatol Sci 2011;64:39-44.
12. Patani N, Jiang W, Mansel R, Newbold R, Mokbel K. The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int 2009;9:18.
13. Tu W, Luo M, Wang Z, Yan W, Xia Y, Deng H, et al. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver Int 2012;32:1064-78.
14. Shukla S, Sharma H, Abbas A, MacLennan GT, Fu P, Danielpour D, et al. Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression. PLoS ONE 2013;8:e53527.
15. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 2008;452:187-93.
16. Lu X, Cheng C, Zhu S, Yang Y, Zheng L, Wang G, et al. SATB1 is an independent prognostic marker for gastric cancer in a Chinese population. Oncol Rep 2010;24:981-7.
17. Cheng C, Lu X, Wang G, Zheng L, Shu X, Zhu S, et al. Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS 2010;118:855-63.
18. Klingelhofer J, Grum-Schwensen B, Beck MK, Knudsen RS, Grigorian M, Lukanidin E, et al. Anti-S100A4 antibody suppresses metastasis formation by blocking stroma cell invasion. Neoplasia 2012;14:1260-8.
19. Sherbet GV. Metastasis promoter S100A4 is a potentially valuable molecular target for cancer therapy. Cancer Lett 2009;280:15-30.
20. Huang L, Xu Y, Cai G, Guan Z, Cai S. Downregulation of S100A4 expression by RNA interference suppresses cell growth and invasion in human colorectal cancer cells. Oncol Rep 2012;27:917-22.
21. Garrett SC, Varney KM, Weber DJ, Bresnick AR. S100A4, a mediator of metastasis. J Biol Chem 2006;281:677-80.
22. Boye K, Maelandsmo GM. S100A4 and metastasis: a small actor playing many roles. Am J Pathol 2010;176:528-35.
23. Sack U, Walther W, Scudiero D, Selby M, Kobelt D, Lemm M, et al. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst 2011;103:1018-36.
24. Mazzucchelli L. Protein S100A4: too long overlooked by pathologists? Am J Pathol 2002;160:7-13.
25. Helfman DM, Kim EJ, Lukanidin E, Grigorian M. The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer 2005;92:1955-8.
26. Mishra SK, Siddique HR, Saleem M. S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence. Cancer Metastasis Rev 2012;31:163-72.
27. Kim JH, Kim CN, Kim SY, Lee JS, Cho D, Kim JW, et al. Enhanced S100A4 protein expression is clinicopathologically significant to metastatic potential and p53 dysfunction in colorectal cancer. Oncol Rep 2009;22:41-7.
28. Gongoll S, Peters G, Mengel M, Piso P, Klempnauer J, Kreipe H, et al. Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology 2002;123:1478-84.
29. Zeng ZL, Wu WJ, Yang J, Tang ZJ, Chen DL, Qiu MZ, et al. Prognostic relevance of melanoma antigen D1 expression in colorectal carcinoma. J Transl Med 2012;10:181.
30. Tang H, Wang J, Bai F, Zhai H, Gao J, Hong L, et al. Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer. Cancer Invest 2008;26:60-7.
31. Mao L, Yang C, Wang J, Li W, Wen R, Chen J, et al. SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion. J Transl Med 2013;11:111.
32. Kohwi-Shigematsu T, Poterlowicz K, Ordinario E, Han HJ, Botchkarev VA, Kohwi Y. Genome organizing function of SATB1 in tumor progression. Semin Cancer Biol 2013;23:72-9.
33. Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M. The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst 2010;102:1284-96.
34. Kohwi-Shigematsu T, Han HJ, Russo J, Kohwi Y. Re: the role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst 2010;102:1879-80; author reply 80-1.
35. Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol 2011;6:1179-89.
36. Al-Sohaily S, Henderson C, Selinger C, Pangon L, Segelov E, Kohonen-Corish MR, et al. Loss of special AT-rich sequence-binding protein 1 (SATB1) predicts poor survival in patients with colorectal cancer. Histopathology 2014;65:155-63.
37. Nodin B, Johannesson H, Wangefjord S, O'Connor DP, Lindquist KE, Uhlén M, et al. Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer. Diagn Pathol 2012;7:115-23.
38. Zhang J, Zhang B, Zhang X, Sun Y, Wei X, McNutt MA, et al. SATB1 expression is associated with biologic behavior in colorectal carcinoma in vitro and in vivo. PLoS ONE 2013;8:e47902.
39. Yonemura Y, Endou Y, Kimura K, Fushida S, Bandou E, Taniguchi K, et al. Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res 2000;6:4234-42.
40. Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O, Maelandsmo GM. Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol 2004;17:990-7.
41. Merzak A, Parker C, Koochekpour S, Sherbet GV, Pilkington GJ. Overexpression of the 18A2/mts1 gene and down-regulation of the TIMP-2 gene in invasive human glioma cell lines in vitro. Neuropathol Appl Neurobiol 1994;20:614-9.
42. Davies MP, Rudland PS, Robertson L, Parry EW, Jolicoeur P, Barraclough R. Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. Oncogene 1996;13:1631-7.
43. Flatmark K, Pedersen KB, Nesland JM, Rasmussen H, Aamodt G, Mikalsen SO, et al. Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J Pathol 2003;200:589-95.
44. Cho YG, Kim CJ, Nam SW, Yoon SH, Lee SH, Yoo NJ, et al. Overexpression of S100A4 is closely associated with progression of colorectal cancer. World J Gastroenterol 2005;11:4852-6.
45. Kriajevska M, Tarabykina S, Bronstein I, Maitland N, Lomonosov M, Hansen K, et al. Metastasis-associated Mts1 (S100A4) protein modulates protein kinase C phosphorylation of the heavy chain of nonmuscle myosin. J Biol Chem 1998;273:9852-6.
46. Zhang HY, Zheng XZ, Wang XH, Xuan XY, Wang F, Li SS. S100A4 mediated cell invasion and metastasis of esophageal squamous cell carcinoma via the regulation of MMP-2 and E-cadherin activity. Mol Biol Rep 2012;39:199-208.